Edition:
United States

Interleukin Genetics Inc (ILIU.PK)

ILIU.PK on OTC Markets Group

0.11USD
9 Dec 2016
Change (% chg)

$-0.00 (-1.79%)
Prev Close
$0.11
Open
$0.13
Day's High
$0.13
Day's Low
$0.10
Volume
23,736
Avg. Vol
36,224
52-wk High
$0.41
52-wk Low
$0.01

Latest Key Developments (Source: Significant Developments)

Interleukin Genetics posts Q2 loss of $0.01/share
Tuesday, 16 Aug 2016 08:00am EDT 

Interleukin Genetics Inc: Interleukin Genetics reports second quarter 2016 financial results . Q2 revenue $590,000 versus $376,000 .Q2 loss per share $0.01.  Full Article

Interleukin Q1 loss per share $0.01
Monday, 16 May 2016 08:00am EDT 

Interleukin Genetics Inc : Interleukin genetics reports first quarter 2016 financial results . Q1 loss per share $0.01 .Q1 revenue $961,000 versus $403,000.  Full Article

Interleukin Genetics appoints Mark B. Carbeau as CEO
Tuesday, 7 Apr 2015 08:00am EDT 

Interleukin Genetics Inc:Appoints Mark B. Carbeau as Chief Executive Officer and Director.Says Dr. Kenneth S. Kornman, DDS, PhD, who served as the President and CEO since August 2012, will continue to serve as President, Chief Scientific Officer and a Director.  Full Article

Interleukin Genetics expands its collaboration with Isis Pharmaceuticals for Genetic Testing Services
Monday, 9 Mar 2015 08:00am EDT 

Interleukin Genetics Inc:Announced that under the terms of its collaboration agreement with Isis Pharmaceuticals.Says the Company will provide Isis with testing kits and will prepare DNA, run genotypes and provide data for SNP genotypes for the IL-1 and LP(a) SNPs for Isis' Phase 1 clinical study evaluating its novel therapeutic, ISIS-APO(a)-LRxin healthy volunteers with elevated lipoprotein.Lp is an independent risk factor for cardiovascular disease.Says this Phase I study is the second Isis clinical study to incorporate Interleukin's genetic test into the trial design to add genetic information at the earliest phases of testing of their new product lines.  Full Article

Interleukin Genetics announces collaboration with Isis Pharmaceuticals for genetic testing services
Wednesday, 7 Jan 2015 08:00am EST 

Interleukin Genetics Inc:Says an agreement with Isis Pharmaceuticals Inc. to provide genetic testing services for Isis' Phase 2 clinical study evaluating its novel therapeutic, ISIS-APO(a)Rx, in patients with high lipoprotein(a), or Lp(a), an independent risk factor for cardiovascular disease.  Full Article